Key result
Hypertension is not associated with severe illness or death in hospitalized COVID-19 patients.
Why the study?
In the absence of effective COVID-19 therapy, identifying determining factors for severe disease is needed, particularly regarding systemic arterial hypertension as a major associated comorbidity.
Cross-Sectional (n=380)
No
Answers are grounded in this paper and cite their sources.
Hypertension should not guide risk stratification in hospitalized COVID-19; observational data leave its broader prognostic role open.
Background In view of the absence of effective therapy for COVID-19, many studies have been conducted seeking to identify determining factors for the development of severe forms, aiming to direct efforts to avoid the worst outcomes in patients susceptible to severe conditions. One of the main comorbidities associated with complicated forms of the disease is systemic arterial hypertension (SAH). Objective To assess aspects of the clinical, demographic, laboratory, and radiological characteristics of hypertensive patients with COVID-19 to contribute to the knowledge of the relationship between the presence of this comorbidity and the severity of the disease. Methods A total of 380 patients with a diagnosis of acute SARS-CoV-2 infection hospitalized between June and August 2020 were included. Patients were divided into two groups according to the presence or absence of a previous diagnosis of hypertension. For comparison between groups, a significant difference was established if p < 0.05. Results Of the total of 380 patients, 202 (53.16%) had a clinical diagnosis of SAH. Hypertensive patients were significantly older (p < 0.01) and had more comorbidities (p < 0.01) than the non-hypertensive group. In laboratory tests, hypertensive patients had higher levels of blood glucose (p = 0.014), creatinine (p = 0.002), and urea (p = 0.003), while values for alanine aminotransferase (ALT) (p < 0.01), aspartate aminotransferase (AST) (p = 0.006), and sodium (p = 0.024) were lower. There was no difference between groups in radiographic parameters. Conclusions This study showed that, although the hypertensive group had some laboratory alterations that elicited severe disease, these patients did not have worse outcomes.
No takes yet. Share an insight, caveat, or question.
Xavier et al. (2023) conducted a cross-sectional in COVID-19 (acute SARS-CoV-2 infection) and Systemic Arterial Hypertension (n=380). Systemic arterial hypertension (SAH) vs. Non-hypertensive COVID-19 patients was evaluated on Severe COVID-19 illness (p=0.757). Systemic arterial hypertension was not associated with higher rates of severe illness (65.7% vs 61.1%, p=0.757) or death (16.0% vs 13.6%, p=0.891) in hospitalized COVID-19 patients.
Synapse has enriched 10 related papers. Consider them for comparative context: